CytomX Therapeutics, Inc. cotiza a 2.33 USD y tiene una capitalización bursátil de $507M. En los últimos 12 meses ha facturado $18M con un margen de flujo de caja libre del -99.5%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets f…
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-03 |
|---|---|---|---|---|
| Real | — | $-0.09 | $-0.10 | $-0.22 |
| Estimado | $-0.07 | $-0.10 | $-0.11 | $-0.09 |
| Sorpresa | — | +10.0% | +9.1% | -144.4% |
| Métrica | CTMX | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -29.4% | -38.6% | +9.3% |
| Net Margin | -22.8% | -33.6% | +10.8% |
| FCF Margin | -99.5% | -13.9% | -85.6% |
| ROE | -17.5% | -40.4% | +22.9% |
| ROA | -11.5% | -32.0% | +20.5% |
| Current Ratio | 3.09 | 2.84 | +0.25 |
| Debt / Equity | — | 0.28 | — |